News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lundbeck Inc. (LUN.CO) Presents New Data on Selincro From Three Phase III Studies That Consistently Show a Significant Reduction in Alcohol Consumption in Alcohol Dependent Patients With High Risk Drinking Level


4/8/2013 11:35:12 AM

Valby, 2013-04-08 08:00 CEST (GLOBE NEWSWIRE) --

• Patients treated with Selincro┬« (nalmefene) showed a reduction in total alcohol consumption after 6 months of 57% in study 1 (ESENSE 1)1 and 62% in study 2 (ESENSE 2)2 and after 12 months of 67% in study 3 (SENSE)3 among high risk drinking alcohol dependent patients.

• Selincro is the first and only medicine approved for the reduction of alcohol consumption in patients with alcohol dependence.4

•There is a significant unmet need as alcohol dependence is both underdiagnosed and undertreated. In Europe more than 90% of the patients with alcohol dependence are currently untreated.5,6

H. Lundbeck A/S (Lundbeck) announced today the results of the revised analysis of the Phase III programme that formed the basis for the approval of Selincro® (nalmefene) in the EU on February 25, 2013. Alcohol dependent patients with high risk drinking level (>60g/day for men, >40g/day for women) treated with Selincro showed a significant reduction in total alcohol consumption after 6 months of 57% in study 1 (ESENSE 1)1 and 62% in study 2 (ESENSE 2),2 and after 12 months of 67% in study 3 (SENSE).3 The analyses from these randomized, double-blind, placebo-controlled Phase III studies were presented at the 21st European Congress of Psychiatry (EPA) in Nice, France.


Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES